| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-10-28 | FRM-0334 | frontotemporal dementia (FTD) associated with a granulin deficiency |
preclinical | Forum Pharmaceuticals (USA - MA) | Rare diseases - Neurodegenerative diseases |
| 2014-10-28 | Fibrocaps™/Raplixa™ | hemostasis |
3 | ProFibrix (The Netherlands) | Hemostasis |
| 2014-10-28 | BUPI | oral pain |
2 | Moberg Pharma (Sweden) | CNS diseases |
| 2014-10-27 | AAV5-AAT-PBGD (AMT-021) | acute intermittent porphyria (AIP) |
1 | uniQure (The Netherlands) AIPGENE Consortium | Rare diseases |
| 2014-10-27 | TXA127 (angiotensin) | Limb Girdle Muscular Dystrophy | preclinical | Tarix Orphan (USA - MA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2014-10-27 | Simponi Aria® (golimumab) | polyarticular juvenile idiopathic arthritis in pediatric patients (o through 16 years of age) |
3 | Janssen Research & Development, a J&J company (USA - NJ) | Autoimmune diseases – Inflammatory diseases - Rare diseases - Rheumatic diseases |
| 2014-10-27 | microarray-based non-invasive prenatal test (NIPT) for Down’s syndrome | Down’s syndrome/Trisomy 21 |
Oxford Gene Technology (UK) | Genetic diseases - Diagnostic | |
| 2014-10-27 | PLX-RAD cells | human umbilical cord blood transplantation |
preclinical | Pluristem Therapeutics (Israel) Case Western Reserve University (USA - OH) | Transplantation - Regenerative medicine |
| 2014-10-24 | indatuximab ravtansine (BT-062) | various solid tumours (human carcinomas of the bladder, breast, lung, prostate and pancreas and on head and neck tumours) |
preclinical | Biotest (Germany) | Cancer - Oncology |
| 2014-10-23 | SAGE-547 | essential tremor | 2a | Sage Therapeutics (USA - MA) | CNS diseases - Neurological diseases |
| 2014-10-23 | ALX-0061 | inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosus |
1 | Ablynx (Belgium) AbbVie (USA - IL) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2014-10-23 | palonosetron HCl | chemotherapy-induced nausea and vomiting (CINV) in pediatric patients |
3 | Helsinn (Switzerland) | Cancer - Oncology |
| 2014-10-22 | oral insulin ORMD-0801 | type 1 diabetes mellitus | 2a | Oramed Pharmaceuticals (Israel) | Metabolic diseases |
| 2014-10-22 | STM 434 | ovarian cancer, other solid tumors | 1 | Atara Biotherapeutics (USA - CA) | Cancer - Oncology |
| 2014-10-21 | ßAir bio-artificial pancreas | type 1 diabetes |
Beta-O2 (Israel) | Metabolic diseases | |
| 2014-10-21 | Myrcludex B | chronic hepatitis B chronic hepatitis delta |
2a | Hepatera (Russia) MYR GmbH (Germany) | Infectious diseases |
| 2014-10-21 | Glassia® (alpha-1 antitrypsin) | type 1 diabetes |
Kamada (Israel) | Metabolic diseases | |
| 2014-10-21 | antibody program PC-mAb | cardiovascular diseases |
1 | Athera Biotechnologies (Sweden) | Cardiovascular diseases |
| 2014-10-21 | BI 695502 (biosimilar version of bevacizumab - Avastin®) | non-small cell lung cancer (NSCLC) | 3 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2014-10-20 | NER1006 | patients undergoing screening, surveillance or diagnostic colonoscopy |
2 | Norgine Pharma (The Netherlands) | Gastrointestinal diseases - Digestive diseases |
